Boxer Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Boxer Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-750,000	Closed	-$7.04M	–	21
2024 Q3	$7.04M	Hold	750,000	–	–	0.35%	46
2024 Q2	$6.01M	Hold	750,000	–	–	0.32%	48
2024 Q1	$11.1M	Sell	750,000 -650,000	-46%	-$7.57M	0.55%	42
2023 Q4	$11.4M	Sell	1,400,000 -2,305,133	-62%	-$12.1M	0.57%	32
2023 Q3	$16.9M	Hold	3,705,133	–	–	0.9%	34
2023 Q2	$26.1M	Hold	3,705,133	–	–	1.21%	30
2023 Q1	$22.6M	Buy	3,705,133 +2,200,000	+146%	+$15.2M	1.11%	30
2022 Q4	$9.62M	Sell	1,505,133 -430,000	-22%	-$3.36M	0.51%	43
2022 Q3	$18.5M	Hold	1,935,133	–	–	1.04%	34
2022 Q2	$21.4M	Hold	1,935,133	–	–	1.35%	26
2022 Q1	$32.2M	Buy	1,935,133 +835,133	+76%	+$12.9M	1.66%	19
2021 Q4	$21M	Hold	1,100,000	–	–	0.82%	30
2021 Q3	$27.1M	Buy	+1,100,000	New	+$25.9M	0.95%	32
2020 Q3	–	Sell	-200,000	Closed	-$5.49M	–	76
2020 Q2	$5.49M	Buy	+200,000	New	+$6.58M	0.24%	57

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Boxer Capital's IOVA Position: Q4 2024 in Review

Boxer Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 750,000 shares — an estimated $7.04M sold.

Boxer Capital first reported a position in IOVA in Q2 2020 and held it in 14 quarters. The position peaked at $32.2M in Q1 2022. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

Boxer Capital reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 750,000 Iovance Biotherapeutics shares in Q4 2024, an estimated $7.04M.
Boxer Capital first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 14 quarters.
Boxer Capital's Iovance Biotherapeutics position peaked at $32.2M in Q1 2022.
301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.